eicosapentaenoic acid ethyl ester has been researched along with Atheroma in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Though statin therapy is known to slow coronary atherosclerosis progression and reduce cardiovascular (CV) events, significant CV risk still remains." | 3.01 | Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results. ( Bhatt, DL; Budoff, MJ; Kinninger, A; Lakshmanan, S; Le Pa, VT; May, HT; Muhlestein, JB; Nelson, JR; Roy, SK; Shaikh, K; Shekar, C; Tayek, J, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chapman, MJ | 1 |
| Zamorano, JL | 1 |
| Parhofer, KG | 1 |
| Sykes, R | 1 |
| McFarlane, R | 1 |
| Budoff, MJ | 2 |
| Muhlestein, JB | 1 |
| Bhatt, DL | 2 |
| Le Pa, VT | 1 |
| May, HT | 1 |
| Shaikh, K | 1 |
| Shekar, C | 1 |
| Kinninger, A | 1 |
| Lakshmanan, S | 2 |
| Roy, SK | 1 |
| Tayek, J | 1 |
| Nelson, JR | 3 |
| Wani, OR | 1 |
| Le, V | 2 |
| Patel, DK | 1 |
| Nelson, A | 1 |
| Nemiroff, RL | 1 |
| Budoff, M | 1 |
| True, WS | 1 |
| Mason, RP | 1 |
3 reviews available for eicosapentaenoic acid ethyl ester and Atheroma
| Article | Year |
|---|---|
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Topics: Adult; Atherosclerosis; Cardiovascular Diseases; Coronary Artery Disease; Eicosapentaenoic Acid; Hea | 2022 |
EPA's pleiotropic mechanisms of action: a narrative review.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Eicosapentaenoic Acid; Humans; Lipid Regulating Agents; P | 2021 |
Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
Topics: Atherosclerosis; Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Plaqu | 2017 |
1 trial available for eicosapentaenoic acid ethyl ester and Atheroma
| Article | Year |
|---|---|
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Computed Tomography Angiography; Coronary Angiography; C | 2021 |
2 other studies available for eicosapentaenoic acid ethyl ester and Atheroma
| Article | Year |
|---|---|
Icosapent ethyl and plaque regression: insights from the EVAPORATE-FFRCT study.
Topics: Computed Tomography Angiography; Fractional Flow Reserve, Myocardial; Humans; Hydroxymethylglutaryl- | 2023 |
The EVAPORATE trial provides important mechanistic data on plaque characteristics that have relevance to the REDUCE-IT results and clinical use of icosapent ethyl.
Topics: Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Plaque, Atherosclerotic | 2021 |